YUANDA Launches Novel Hybrid Peptide Formulation Bridging Weight Loss and Skin Health
Early in vitro studies suggest the hybrid peptide may support appetite control while stimulating fibroblast activity, potentially opening new avenues for integrated metabolic and dermatological research. YUANDA plans to make research‑grade samples available to qualified laboratories by the third quarter of this year.
“We are moving beyond single‑purpose peptides,” said a company spokesperson. “Our goal is to provide researchers with tools that address the growing intersection of metabolic health and aesthetic science.”
YUANDA Launches Novel Hybrid Peptide Formulation Bridging Weight Loss and Skin Health
Hong Kong – YUANDA Co., Ltd. has announced the development of a proprietary hybrid peptide formulation that targets both metabolic regulation and dermal rejuvenation. The new compound, designated YD‑GLP‑M, combines a GLP‑1 receptor agonist sequence with a collagen‑boosting peptide motif, offering a dual‑action profile for research applications.
Early in vitro studies suggest the hybrid peptide may support appetite control while stimulating fibroblast activity, potentially opening new avenues for integrated metabolic and dermatological research. YUANDA plans to make research‑grade samples available to qualified laboratories by the third quarter of this year.
“We are moving beyond single‑purpose peptides,” said a company spokesperson. “Our goal is to provide researchers with tools that address the growing intersection of metabolic health and aesthetic science.”